Login to Your Account



Shire Gets Ex-U.S. Rights

LSD Deal Brings Amicus $50M Now, $390M Later

By Trista Morrison


Friday, November 9, 2007
In a deal that could top $440 million, Amicus Therapeutics Inc. teamed up with Shire Human Genetic Therapies Inc. on the ex-U.S. development and commercialization of Amicus's three lead pharmacological chaperone compounds for lysosomal storage disorders (LSDs): Amigal, Plicera and AT2220. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription